Answer
Fezolinetant is not recommended for women with severe renal impairment or end-stage renal disease because long-term safety data are lacking in this population.
Sources for this answer
- Veoza 45 mg film-coated tabletsAstellas Pharma Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 5Document updated
Sources checked